Cytek Biosciences, Inc. (NASDAQ:CTKB - Get Free Report) CTO Ming Yan sold 20,000 shares of Cytek Biosciences stock in a transaction dated Friday, April 19th. The stock was sold at an average price of $5.87, for a total value of $117,400.00. Following the sale, the chief technology officer now directly owns 5,988,502 shares in the company, valued at $35,152,506.74. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Ming Yan also recently made the following trade(s):
- On Tuesday, April 9th, Ming Yan sold 1,900 shares of Cytek Biosciences stock. The stock was sold at an average price of $7.00, for a total value of $13,300.00.
- On Monday, March 18th, Ming Yan sold 20,000 shares of Cytek Biosciences stock. The stock was sold at an average price of $6.77, for a total value of $135,400.00.
Cytek Biosciences Trading Up 0.2 %
NASDAQ:CTKB opened at $5.81 on Wednesday. The firm has a market capitalization of $760.06 million, a price-to-earnings ratio of -64.55 and a beta of 1.37. Cytek Biosciences, Inc. has a 1-year low of $3.80 and a 1-year high of $12.31. The business's fifty day moving average price is $7.13 and its 200 day moving average price is $7.09.
Global crypto currency reset (41 major banks signed up)
From Stansberry Research | Ad
Behind closed doors, at least 41 major US banks have signed up to a strange new crypto project...
Here's everything you need to know.
Cytek Biosciences (NASDAQ:CTKB - Get Free Report) last released its quarterly earnings results on Wednesday, March 13th. The company reported $0.04 earnings per share (EPS) for the quarter. The company had revenue of $58.23 million during the quarter, compared to the consensus estimate of $56.66 million. Cytek Biosciences had a negative return on equity of 1.40% and a negative net margin of 6.29%. Equities analysts forecast that Cytek Biosciences, Inc. will post -0.04 earnings per share for the current year.
Institutional Trading of Cytek Biosciences
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. grew its holdings in shares of Cytek Biosciences by 7.3% during the 4th quarter. Vanguard Group Inc. now owns 11,890,700 shares of the company's stock worth $108,443,000 after purchasing an additional 811,279 shares in the last quarter. New York State Common Retirement Fund raised its position in shares of Cytek Biosciences by 25.6% during the fourth quarter. New York State Common Retirement Fund now owns 2,947,986 shares of the company's stock worth $26,886,000 after acquiring an additional 599,971 shares during the last quarter. Wellington Management Group LLP raised its position in shares of Cytek Biosciences by 7.4% during the third quarter. Wellington Management Group LLP now owns 1,445,538 shares of the company's stock worth $7,979,000 after acquiring an additional 99,170 shares during the last quarter. Charles Schwab Investment Management Inc. grew its stake in shares of Cytek Biosciences by 5.3% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 880,038 shares of the company's stock worth $8,026,000 after purchasing an additional 44,345 shares during the period. Finally, Bank of New York Mellon Corp grew its stake in shares of Cytek Biosciences by 8.6% during the third quarter. Bank of New York Mellon Corp now owns 825,580 shares of the company's stock worth $4,557,000 after purchasing an additional 65,551 shares during the period. Institutional investors and hedge funds own 69.46% of the company's stock.
Analyst Ratings Changes
CTKB has been the subject of several analyst reports. The Goldman Sachs Group upped their target price on Cytek Biosciences from $9.00 to $10.00 and gave the company a "buy" rating in a report on Thursday, February 29th. Piper Sandler reduced their target price on Cytek Biosciences from $11.00 to $10.00 and set an "overweight" rating for the company in a report on Wednesday, March 6th. Two investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $9.00.
Get Our Latest Analysis on Cytek Biosciences
About Cytek Biosciences
(
Get Free Report)
Cytek Biosciences, Inc, a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; aurora CS systems; amnis imagestream imaging flow cytometers; guava muse cell analyzers; guava easycyte flow cytometers; and orion reagent cocktail preparation systems.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
